Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Immunology
- General Oncology
- Head and Neck Oncology
- Sarcomas
- Radiation Therapy
- Cervical Cancer
- Prostate Cancer
- Chemotherapy and Radiotherapy
Abstract
Citation: Clin Oncol. 2022;7(1):1978.DOI: 10.25107/2474-1663.1978
Malignant Struma of the Ovary: Own Clinical Observation
Kiseleva MV, Denisov MS, Lunkova MN, Karibayeva ShK and Litvyakova EV
A. Tsyb Medical Radiological Research Center, National Medical Research Radiological Center of the Ministry of Health of the Russian Federation (A. Tsyb MRRC) 249036, Russia
International Clinical Center of Reproductology PERSONA, Kazakhstan
*Correspondance to: Litvyakova Elena Viktorovna
PDF Full Text Case Report | Open Access
Abstract:
Ovarian teratomas account for 15% to 20% of all ovarian tumors. Ovarian Struma (OS) in most cases (up to 50%) refers to monodermal mature ovarian teratoma and is a fairly rare tumor consisting of thyroid tissue. This type of neoplasm accounts for 1% of all ovarian tumors and 2.7% of all dermoid formations. The diagnosis of "ovarian struma" is made if the thyroid tissue is more than 50% of the tumor tissue. The article describes his own experience in managing a patient with a diagnosis of "Malignant struma of the ovary". Data on the clinical and morphological features of the disease are given.
Keywords:
Cite the Article:
Kiseleva MV, Denisov MS, Lunkova MN, Karibayeva ShK, Litvyakova EV. Malignant Struma of the Ovary: Own Clinical Observation. Clin Oncol. 2022;7:1978..